Jilin Aodong Pharmaceutical Group Co., Ltd.

Jilin Aodong Pharmaceutical Group Co., Ltd. is a pharmaceutical manufacturing company based in China, listed on the Shenzhen Stock Exchange since 1996. The company traces its origins to the state-owned Yanbian Dunhua Deer Farm established in 1957 and has evolved through various stages, including the establishment of Aodong Pharmaceutical Factory in 1981 and the formation of a holding group in 2001. Jilin Aodong is committed to producing safe, reliable, and trustworthy medicines, emphasizing the traditional virtue of "relieving the world" and the business philosophy of "the health of the world, Aodong's responsibility." The company primarily focuses on the research, development, manufacturing, and sales of traditional Chinese medicine and chemical drugs. Its product offerings include traditional Chinese patent medicines, herbal formula granules, and chemical drugs, while also expanding into health food and related industries. Jilin Aodong has developed a multi-faceted business model that integrates medicine, finance, and the broader health industry, positioning itself as a competitive player in the pharmaceutical sector. The company operates three modern industrial bases in Jilin Province and is recognized for its commitment to quality and technological innovation in manufacturing.

1. The Aodong brand advantage of inheriting traditional Chinese medicine culture and promoting the essence of Chinese medicine The "Aodong Jitu" trademark is a valuable intangible asset formed by the company's establishment of a pharmaceutical factory for more than 40 years, inheriting traditional Chinese medicine culture, promoting the essence of Chinese medicine, and undergoing brand establishment, expansion, and maintenance. In December 1999, it was recognized as a Chinese famous trademark by the Trademark Office of the State Administration for Industry and Commerce. As a symbol of the enterprise and a guarantee of quality, the "Aodong" brand has been selected as one of the "China's 500 Most Valuable Brands" by the World Brand Lab for 18 consecutive years, with a brand value of 13.194 billion yuan. In May 2024, the brand value evaluation results of the China Brand Building Promotion Association showed that the brand strength of Jilin Aodong was 902 and the brand value was 11.683 billion yuan. The company was recognized as a "Jilin Time-Honored Brand" by the Jilin Provincial Department of Commerce in August 2014. In February 2024, the "Aodong" brand was recognized as the third batch of " China’s Time-Honored Brand " by the Ministry of Commerce, the Ministry of Culture and Tourism, the State Administration for Market Regulation, the State Intellectual Property Administration, and the State Administration of Cultural Heritage. Jilin Aodong has gained high market recognition for its strong brand culture and excellent product quality. 2. Every medicine, every pill has the quality advantage of being safe, reliable, and reassuring The company always adheres to the original mission of producing "safe, reliable, and trustworthy medicine", implements comprehensive quality management, insists on strict control at the source, process, and risk prevention, and ensures that product quality is even better. The company has a National Enterprise Technology Center and a National Postdoctoral Research Workstation. The company has established internal control standards that are higher than the national legal standards, established the concept of "quality is the life of the enterprise", adhered to the spirit of "craftsmanship", strictly managed product quality, continuously improved drug quality, and strived for excellence in products to ensure that every medicine and every pill is safe, reliable, and reassuring. Yanbian Pharmaceutical has successively won the title of National Industrial Enterprise Quality Benchmark, High tech Enterprise, Jilin Province Quality Award, Excellent Brand Enterprise of Chinese Medicine, Leading Brand of Health and Pharmaceutical Industry, Five star Integrity Enterprise in 2023, Initiative Unit for Cultivating Integrity Management and Trustworthy Practice Benchmark Enterprise, Integrity Demonstration Management Certification Enterprise, and participated in drafting two group standards: "National Integrity Management Demonstration Enterprise Requirements" (T/CERDS 6-2023) and "National Excellent Integrity Entrepreneur Requirements" (T/CERDS 7-2023). 3. The technological advantages of intelligent manufacturing and digital lean production The company adheres to craftsmanship in pharmaceuticals, upholds excellent quality, and continues to promote the inheritance and development of traditional Chinese medicine culture. We always adhere to the core values of "focusing on people and specializing in medicine", adhere to the development path of "promoting enterprises through science and technology" and "strengthening enterprises through science and technology", constantly innovate in technology, adopt full process online detection and analysis technology in production, establish an automated production line for traditional Chinese medicine extraction, adopt advanced technologies such as modern biological chromatography separation, centrifugal separation, and organic solvent classification and precipitation, promote lean production, and gradually transform the production process from automation and informatization to intelligence and digitization. Yanbian Pharmaceutical is a demonstration factory for intelligent manufacturing in Jilin Province. In order to enhance production capacity and consolidate the comprehensive capabilities of the pharmaceutical industry, the company has built an advanced, energy-saving, environmentally friendly, and fully functional Aodong Industrial Park industrial cluster in Dunhua City, established a high-tech pharmaceutical park in Yanji City, and established a phytochemical drug production base in Taonan City. 4. Innovative modern enterprise system activates the management advantages of enterprise vitality The company continuously innovates and improves its modern corporate system, transforming into a holding group company with a "parent-subsidiary corporation" management system. The parent company organizes the formulation and implementation of the group's long-term plans and development strategies, and carries out capital operation activities such as investment and financing, corporate mergers and acquisitions. The subsidiary operates flexibly and enjoys the right to operate independently, implementing specific research and development, production, and sales enterprise operations. The parent subsidiary system enhances the group combination effect, making the overall development of the company dynamic and sustainable. Over the years, the company has continuously improved its corporate governance structure and established a mature parent subsidiary management system; By implementing ESOP, a community of shared interests between the company and its employees can be formed, promoting mutual growth between employees and the company, and jointly promoting the continuous development and growth of the company; By deepening the reform of personnel system, restructuring the selection mechanism, innovating the evaluation system, a professional, pragmatic, and compliant management team has been created, injecting endogenous power into the high-quality development of the company. 5. The capital advantage of combining industry and finance through holding high-quality financial assets The company has established a multi wheel driven development model of "medicine+ finance+ big health industry ", using financial advantages to support the development of physical industries. The company has always been committed to the development of the pharmaceutical industry, and has become the largest shareholder of GF Securities Co., Ltd. through investing in its equity and timely market value management. GF Securities Co., Ltd. is the core high-quality asset of the company and has established a core position of capital advantage. Becoming the second shareholder of Shanghai NO.1 Pharmacy Co., Ltd., the third shareholder of NanJing Pharmaceutical Company Limited, the fourth shareholder of Liaoning Cheng Da Co., Ltd., and investing in some listed companies in the pharmaceutical industry through equity investment. At the same time, cooperating with GF Investment Management‌‌ to establish a fund to select pharmaceutical enterprises for investment, and using equity investment as a link to explore business cooperation opportunities.